Jazz Pharmaceuticals plc
Jazz Pharmaceuticals Reports Third Quarter 2025 Financial Results and Updates Guidance
Summary
Jazz Pharmaceuticals plc announced its third quarter 2025 financial results, showing total revenues of $1.13 billion, a 7% increase year-over-year. The company reported GAAP net income of $251.4 million and non-GAAP adjusted net income of $500.7 million for the quarter. Jazz Pharmaceuticals also updated its full-year 2025 financial guidance, narrowing the total revenue range to $4.175 - $4.275 billion and maintaining non-GAAP adjusted net income guidance between $475 - $525 million. Notable product updates include strong sales of Epidiolex and Xywav, and the FDA approval of Modeyso for recurrent H3 K27M-mutant DMG.
Profitelligence Alerts
Get alerts for JAZZ
Be first to know when Jazz Pharmaceuticals plc files with the SEC.
Filing Categories
Advertisement
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company that focuses on developing life-changing medicines for patients in various therapeutic areas. The company's primary function is to research, manufacture, and market drugs that address unmet medical needs, particularly in the fields of neuroscience, oncology, and sleep medicine. Jazz Pharmaceuticals has gained prominence for its innovative products such as Xyrem, used for treating narcolepsy, and Vyxeos, a treatment for certain types of leukemia. Headquartered in Dublin, Ireland, the company operates extensively across North America and Europe, working to advance scientific research in pharmaceuticals. By prioritizing patient care and survival, Jazz Pharmaceuticals plays a significant role in the pharmaceutical industry with its commitment to developing novel therapies. Moreover, the company's strategic collaborations and acquisitions enable it to expand its product portfolio and impact the healthcare sector positively. Jazz Pharmaceuticals continues to be a key player in transforming patient care for complex conditions.
Official SEC Documents
Advertisement